REZUROCK 20 MG TAB (BELUMOSUDIL)

🧬 Indication

       Rezurock is FDA-approved for:

• Treatment of chronic graft-versus-host disease (cGVHD) in patients aged 12 years and older, who have failed at least two prior lines of systemic therapy.

             cGVHD is a serious complication that occurs after an allogeneic stem cell transplant, where the donor’s immune cells attack the patient’s body.

💊 Formulation & Strength

• Dosage Form: Oral tablet

• Available Strength: 200 mg tablet

🧪 Recommended Dose

• 200 mg once daily

• Taken with or without food

• Swallow whole; do not crush or chew

⚠️ Side Effects

    Common:

• Fatigue

• Nausea

• Diarrhea

• Shortness of breath

• Increased liver enzymes (AST, ALT)

• Headache

• Muscle pain

• High blood pressure

    Serious:

• Liver toxicity (requires liver function monitoring)

• Cytopenias (reduction in blood cell counts)

• Infection risk

🚫 Warnings & Precautions

• Monitor liver function tests regularly

• Use caution with CYP3A inhibitors or inducers

• Not recommended in pregnancy or breastfeeding

⚠️ Drug Interactions

        Avoid or adjust dose when using:

• Strong CYP3A inhibitors (e.g., ketoconazole)

• Strong CYP3A inducers (e.g., rifampin)

✅ Conclusion

         Rezurock (belumosudil) is the first-in-class ROCK2 inhibitor, offering a targeted therapy option for patients with chronic GVHD who have

          limited treatment choices. It helps improve organ function and quality of life, but requires regular monitoring due to risks of liver

          toxicity and immunosuppression.